

会议指南

# APS 30周年庆典学术报告会 暨中国药理学会常务理事会议


2010年8月31日-9月2日 上海

主办单位：中科院上海药物研究所

协办单位：中国药理学会，上海药理学会



《中国药理学报》(Acta Pharmacologica Sinica, APS)是我国创办的优秀学术期刊之一,由中国药理学会和中科院上海药物研究所主办。30年来在海内外编委和科学家们的共同努力下,APS为我国生物医药的学术传播做出了重要的贡献。2009年起APS与国际知名的Nature Publishing Group合作出版,目前SCI影响因子为1.783。APS连续获得国家自然科学基金、中科院出版基金一等、中国科协精品期刊工程A类等资助。为了庆祝APS创刊30周年,促进海内外学术交流,中科院上海药物研究所将于2010年8月31日-9月2日举办APS 30周年庆典学术报告会暨中国药理学会常务理事会议。



主编: 丁健

荣誉主编: 丁光生

副主编: 杜冠华, 胡国渊, 苏定冯, 左建平

顾问: 陈凯先, Cheng Yung-Chi, 池志强, Grillner Sten, Hofmann Franz, 金国章, 李晓玉, 林志彬, 桑国卫, Vanhoutte Paul M, 张均田



## Introduction of speakers



Prof. Alexei Verkhratsky, MD, PhD, DSc, Member of Academia Europaea. He graduated from Kiev Medical Institute in 1983, and received PhD in physiology from Bogomoletz Institute of Physiology (Kiev, Ukraine) in 1986. In 1993 he was awarded the degree of Doctor of Science from the same institute. From 1990 to 1995 A. Verkhratsky was Head of Laboratory of Cellular Signalling in Bogomoletz Institute of Physiology. In 1992 - 1995 he also was a Deputy Director of the International Centre of Molecular Physiology, Kiev, The Ukraine. Between 1995 and 1999 A. Verkhratsky was a Research Scientist at Max Delbrück Centre of Molecular Medicine in Berlin. He joined the Division of Neuroscience, School of Biological Sciences in Manchester in September 1999, became a Professor of Neurophysiology in 2002 and served as Head of the said Division from 2002 to 2004. From 2007 he was appointed as a visitor professor/Head of Department of Cellular and Molecular Neurophysiology at the Institute of Experimental Medicine, Academy of Sciences of Check Republic.

Prof. Alexei Verkhratsky was elected to membership of Academia Europaea in 2003, and from 2006 he is a Chairman of the Physiology and Medicine section. He is editor-in-chief of *Cell Calcium* (2000), and *Membrane Transport & Signalling - Wiley Interdisciplinary Reviews* (2009) and member of editorial boards of *Pflugers Archiv European Journal of Physiology*, *Journal of Molecular & Cellular Medicine*, *Acta Physiologica* (Oxford), *Acta Pharmacologica Sinica* (2005), *Glia* (2008), *Frontiers in Neuropharmacology*, *Frontiers in Aging Neuroscience*, *Cell Death & Disease* (2009) and *Purinergic Signalling* (2010). He delivered more than 160 international invited lectures and seminars.

Prof. Alexei Verkhratsky is an internationally recognised scholar in the field of cellular neurophysiology. His research is concentrated on the mechanisms of inter- and intracellular signalling in the CNS, being especially focused on two main types of neural cells, on neurones and neuroglia. He made important contributions to understanding the importance of chemical and electrical routes in reciprocal neuronal-glial communications and on the role of intracellular  $\text{Ca}^{2+}$  signals in the integrative processes in the nervous system. Many of A. Verkhratsky's studies are dedicated to investigations of cellular mechanisms of neurodegeneration. In collaboration with Dr. P. Fernyhough, A. Verkhratsky demonstrated that experimental diabetes is associated with disruption of  $\text{Ca}^{2+}$  homeostasis and mitochondrial function; both these systems appear to be regulated by insulin-receptor-dependent signalling cascades. A. Verkhratsky was the first to perform intracellular  $\text{Ca}^{2+}$  recordings in old neurones in isolation and *in situ*, which provided direct experimental support for " $\text{Ca}^{2+}$  hypothesis of neuronal ageing". In recent years he is extending these investigations to characterisation of neuronal and glial pathology in Alzheimer disease.

Scientometry: Prof. Alexei Verkhratsky authored and edited 7 books, edited 18 special issues and published about 250 papers and chapters. His papers were cited about 5800 times, H-index 42 (ISI, 06/2010).



Dr. Zhenping Zhu is currently Executive Vice President, Global Biologics R&D, Kadmon Pharmaceuticals LLC, New York, and President and CEO of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis Biologics from February 2009 to July 2010. At Novartis, Dr. Zhu established and managed biologics research groups globally in Basel (Switzerland), Cambridge (US), and Shanghai (China), and was responsible for the discovery, design and selection of novel biologic drugs, including monoclonal antibodies, recombinant proteins and engineered molecules that address diseases of high unmet need. From 1996 to 2009, Dr. Zhu was Vice President of Antibody Technology and Immunology at ImClone Systems, which was acquired by Eli Lilly in late 2008, and has led research

teams that successfully discovered and engineered several novel antibodies that are currently in phase I to III clinical development for various oncology indications. Dr. Zhu has been working in the area of antibody technologies and biotherapeutics for over 25 years, and has published over 180 peer-reviewed scientific papers, including original research articles, invited reviews and book chapters. Dr. Zhu is also a frequently invited speaker at various international conferences/symposiums in life sciences.

Dr. Zhu earned his medical degree from Jiangxi Medical College and his MSc in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College. He received his PhD in Immunology and Pathology from Dalhousie University, and performed his postdoctoral work in antibody/protein engineering at Genentech Inc. Dr. Zhu is a member of the BayHelix Group (百华协会), an organization of leaders of Chinese heritage in the global life sciences and healthcare community.



Jie Wu, MD, PhD, Dr. Wu obtained his initial faculty appointment in the University of New Mexico, School of Medicine as Assistant Professor (1997.9-1998.8). He joined Barrow Neurological Institute (BNI) in 1998.9 as a Staff Scientist and Director of Neural Physiology Laboratory. In 2000, Dr. Wu was promoted to Associate Staff Scientist. Now, Dr. Wu is currently Senior Staff Scientist (equivalent to full professor) and Director of Neural Physiology Laboratory at BNI. Dr. Wu has established several research projects to study neuronal nicotinic acetylcholine receptor (nAChR) physiology, pharmacology and pathophysiology using both heterologously expressed and natural nAChRs. Dr. Wu is an experienced electrophysiologist, and he has made significant contributions in nAChR study field. The research programs in Dr.

Wu's laboratory have been funded by NIH and other foundations during the past 11 years. Dr. Wu has published more than 100 peer-reviewed articles and 5 book chapters. Dr. Wu is the inventor of 5 US patent applications. In addition, Dr. Wu also is the adjunct professor in Arizona State University (since 2002), Nanjing Medical University (since 2004), Beijing Institute of Pharmacology and Toxicology (since 2005), and Shantou University (Since 2010.6). Dr. Wu carried out his postdoctoral training in both University of New Mexico (USA, 1994-1997) and Tohoku University School of Medicine (Japan, 1993-1994). He received his PhD from Sun Yet-Sen University of Medical Sciences (China, 1985-1990) and his MD from Xuzhou Medical College (China, 1978-1983).





Dayue Darrel Duan, MD (Hunan Medical University, 1982), MSc (Sun Yat-Sen University of Medical Sciences, 1987), PhD (McGill University, 1996), is a Professor of Pharmacology and Director of Laboratory of Cardiovascular Phonomics in the Center of Biomedical Research Excellence and the Department of Pharmacology, University of Nevada, Reno, USA. He is also a Visiting Professor of several prestigious universities in China, including Central South University XiangYa Medical College, Sun Yat-sen University, the Second Military Medical University, the Forth Military Medical University, and Harbin Medical University. He has been studying cellular and molecular electrophysiology and cardiovascular pharmacology for 25 years. He discovered several anion channels in the heart and has made significant contributions to

the study of biophysics, physiology, pharmacology, and molecular biology of ion channels in the cardiovascular system. His current research, supported by NIH, American Heart Association, and American Diabetes Association, is focusing on the functional genomics, proteomics, and phenomics of ion channels in the cardiovascular systems. He has published more than 50 papers and book chapters. His publications often appear in the most prestigious journals including Nature, Physiological Review, Circulation, Circulation Research, Journal of Biological Chemistry, Journal of General Physiology, Journal of Physiology etc. He served on the Research Committee of the Western States Affiliate of American Heart Association. He is currently a member of the Editorial Board of *Acta Pharmacologica Sinica*, Proceedings of Western Pharmacological Society, and World Journal of Cardiology, and a frequent referee for more than 40 professional journals.



Prof. Chi Hin Cho is the Chair Professor of Pharmacology and also the Associate Director of the School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong. He has been the editor, associate editor and also the editorial board member of 26 national and international journals in biomedical sciences. He also published more than 370 peer-reviewed articles, reviews and book chapters in journals and books. Prof. Cho is currently the President of Gastrointestinal Pharmacology Section, the International Union of Basic and Clinical Pharmacology.



Dr. Ming-Hai Wang is a Professor of Amarillo Community Endowed Chair in Cancer Research and the Director of Center for Cancer Biology & Therapeutics. He joined the faculty of the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy as a tenured Professor of Biomedical/Pharmaceutical Sciences in 2004. Dr. Wang received his medical degree (MD) from Zhejiang Medical University (China) and his PhD from a joint program between Zhejiang Medical University and the Medical University of Lübeck (Germany). Dr. Wang pursued postdoctoral training at the Borstel Research Center (Germany) and later at the National Cancer Institute of the NIH where he became a staff member in 1995. He became an Assistant Professor at Wayne State University School of Medicine (Michigan)

and later Associate Professor of Medicine and Cancer Biology at the University of Colorado, School of Medicine in Denver.

During his scientific career, Dr. Wang has received several awards from institutions/ organizations including Federal Ministry for Science & Technology (Germany), NIH Forgardy International Center (USA), and Cheung-Kong Scholars Endowment (China). He has served on various grant evaluation groups including NIH study section and acted as reviewer for journals including Carcinogenesis, Oncogene, Cancer Research, and JBC. Dr. Wang' research focuses on a particular receptor tyrosine kinase in epithelial tumorigenesis. He has studied the RON receptor for the last 19 years and has published more than 80 articles in journals such as Sciences, PNAS, JCI, Oncogene, and JBC. Wang's research is supported by grants from US NIH and other funding agencies. As the Director of the Cancer Biology Center, Dr. Wang works with center members from TTUHSC to develop a strong cancer biology program.

# Program for the APS 30<sup>th</sup> Anniversary Event

—— August 31st, Tuesday ——

**Reception (Invited Only)** Guests from outside of Shanghai

18:00-20:00 **Welcome Dinner**

CEISIP Hotel Shanghai, 1500 Ke-yuan Rd, Zhangjiang Hi-Tech Park

20:00-22:00 **Chinese Pharmacological Society Board Members Meeting**

—— September 1st, Wednesday ——

8:00 am- Shuttle Bus from CEISIP to Shanghai Institute of Materia Medica, CAS

Venue: Cheng-Gu Hall, Shanghai Institute of Materia Medica, CAS

8:15-8:30	Guests sign in
8:30-9:50	<b>APS 30<sup>th</sup> Anniversary Celebration</b> Introduction of the Distinguished Guests Introduction of the APS Development Speech from Editor-in-Chief of APS Speech from President of CPS Speech from the Leader of Nature Publishing Group-Asia Speech from Editorial Board Members Outstanding Contribution Awards to the Authors, Guest Editors, and Founding EIC
9:50-10:20	<b>Group Photo &amp; Coffee Break</b>
10:20-11:00	<b>Alexei Verkhratsky</b> , The University of Manchester, UK Physiology and pathophysiology of neuroglia
11:00-11:40	<b>Zhenping Zhu</b> , Novartis Biologics, USA Research and development of antibody-based therapeutics
11:40-12:20	<b>Jie Wu</b> , Barrow Neurological Institute, USA Mechanisms of nicotine-induced dopamine neuron excitation in the ventral tegmental area
12:20-13:20	<b>Lunch</b>
13:20-14:00	<b>Dayue Duan</b> , University of Nevada at Reno, USA Chloride channels and cardiac diseases: novel mechanisms for cardioprotection?

14:00-14:40	<b>Chi Hin Cho</b> , The Chinese University of Hong Kong A peptide targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery
14:40-15:20	<b>Ming-Hai Wang</b> , Texas Tech University Health Sciences Center, USA Therapeutics targeting the RON/MET receptor tyrosine kinases in malignant epithelial cancers
15:20-15:40	<b>Ning Liu</b> , BIO-RAD workshop Efficient and reliable biomarker validation in drug development
15:40-16:00	<b>Coffee Break</b>

16:00-18:00 **APS Editorial Board Meeting** (Yi-Sheng Hall, Shanghai Institute of Materia Medica, CAS)  
 18:00- Shuttle Bus from Shanghai Institute of Materia Medica to Dinner  
 18:30-21:00 **Dinner** (Invited Only)  
 21:00- Shuttle Bus from Dinner to CEISIP

—— September 2nd, Thursday ——

8:30-20:30 Expo 2010 (Invited Only)

### Hotel Information:

CEISIP Hotel Shanghai, 1500 Ke-yuan Rd, Zhangjiang Hi-Tech Park

In Chinese: 上海信安左城酒店, 张江高科科苑路 1500 号 (曙光医院对面)

Distance from Hongqiao Airport: 35 km

Distance from Pudong Airport: 30 km

Distance from Metro Line 2 Zhangjiang Hi-Tech Park Station: 2 km



## 中国药理学会简介

中国药理学会是由全国药理学工作者自愿组成依法登记成立的学术性、公益性、非盈利性的法人社会团体。由会员、通讯会员和资深会员组成，目前正式注册会员 4000 余人，分别来自于全国药理学相关的大专院校、科研机构、医疗机构、企事业单位、政府机关和医药企业等机构。中国药理学会聚集了全国在药理学相关的教学、科研、应用、生产、科普等领域的优秀药理学家。

中国药理学会的前身是在中国生理科学会和中国药学会药理专业委员会基础上由我国药理学家组织成立的学术团体，最早开始活动于 20 世纪 50 年代，至 1985 年由国家民政部正式批准成立为国家一级学会。

中国药理学会目前设有 18 个专业委员会。各专业委员会研究覆盖了药理学的各个领域，并引领各自领域的学科发展。中国药理学会还主办有 7 种学术期刊，在国内外学术交流中发挥了积极的作用。中国药理学会办公室目前挂靠于中国医学科学院药物研究所，负责每 1~2 年举办一次全国性的学术会议。

中国药理学会和法国施维雅研究院于 1997 年共同设立了"中国药理学会-施维雅青年药理学工作者奖"，该奖项每年评选一次。中国药理学会还设立有"中国药理学会青年药理学工作者奖"，至今已表彰了 33 位优秀的青年药理学家。另外为了表彰老一代药理学家对药理学发展做出的贡献，中国药理学会分别在 1999 年、2007 年、2009 年三次共表彰了 121 位资深药理学家。

中国药理学会已建立了广泛的国际合作关系，目前已经与日本、法国、俄罗斯、英国等国家的药理学会建立了稳定的双边学术交流的合作关系。

中国药理学会经过老一辈药理学家卓越的工作和无私的奉献，各级领导和社会各界的支持，以及全国会员的共同积极努力，目前工作已取得了重大进展。在新的历史时期，中国药理学会正在以新的姿态蓬勃发展。

## Bio-Rad 简介

位于美国加州的 Bio-Rad 公司成立于上世纪五十年代。公司自成立之初，一直致力于为生命科学研究和临床检测提供创新的产品和服务。

在生命科学领域，Bio-Rad 公司的产品涵盖了从基因组学、蛋白组学、细胞生物学到食品安全，生物技术，药物研发等多个领域，为全球 100 多个国家，超过 90000 个用户提供最新的技术和产品，包括电泳、图像、基因扩增(PCR)、层析产品、转基因产品等。

2007 年，Bio-Rad 公司推出了 ProteOn XPR36 生物分子相互作用系统，利用 SPR(表面等离子体共振)技术为药物研发提供高通量，平行分析的技术平台，能够快速筛选先导化合物、测定亲和力等。

Bio-Rad 公司将一如既往地为用户提供更新更全面的产品和优质的服务，来满足用户不同的应用需求。

# 中国科学院上海药物研究所简介


中国科学院上海药物研究所是我国历史最悠久的药物研究机构，前身是国立北平研究院药物研究所，创建于1932年，首任所长为赵承嘏，他是我国运用现代科学方法研究中草药的先驱。1993年，搬迁至上海武康路，1958年搬迁至岳阳路，2003年落户浦东张江高科技园区。

上海药物研究所是以创新药物的基础研究、应用基础和应用开发研究为主的综合性研究所。通过生物学和化学两大学科的密切合作，阐明生物活性物质的结构、活性及其相互关系；探索药物作用的新机理、新靶点；完成新药临床前综合评价及研究；大力推进新药成果转化；为我国创新药物能力的全面提升起到引领、骨干和辐射作用。

上海药物研究所的主要研究领域包括：天然活性物质的发现；化合物的合成、结构修饰；药物作用的细胞和分子机制；药效评价新动物模型；新靶标的确证；药物-靶标相互作用和构效关系；分子药物设计；高通量和高内涵药物筛选；药物的早期代谢特征和安全性评价；药物新型传递系统等。密切关注生命组学、系统生物学和干细胞等生命科学前沿领域最新进展，迅速应用它们的最新成果，提升药物研究的源头创新能力。与此同时，通过上述各个学科领域的综合研究，重点研究治疗肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、抗病毒和自身免疫性疾病等新药；并加强现代中药的研发，发掘祖国医药宝库，为中药走向世界不断作出基础性、战略性的贡献。

上海药物研究所拥有新药研究国家重点实验室、国家新药筛选中心、中药标准化技术国家工程实验室等三个国家级研究机构，设有药物化学研究室、天然药物化学研究室、药理学第一研究室、药理学第二研究室、药理学第三研究室等五个研究室，并建有药物发现与设计中心、药效评价研究中心、药物安全评价研究中心、药物代谢研究中心、药物释放系统研究中心、中药现代化研究中心等一系列新药研发技术平台以及分析化学室、实验动物室、图书情报室和期刊联合编辑部等支撑部门；主办了英文学术杂志《Asian Journal of Andrology》和《Acta Pharmacologica Sinica》，并主办以非处方药物为主的科普杂志《家庭用药》。

经过几代科研人员的努力，上海药物研究所已发展成为学科齐全、成就卓著、人才荟萃、在国内外享有较高声誉的国立药物研究机构。数十年来，上海药物研究所先后研制出了一批重要的创新药物，近十年来又进一步建立和完善了达到国际水平的新药研究技术平台体系，成为我国新药研究代表性机构之一。





# Acta Pharmacologica Sinica



*APS (Acta Pharmacologica Sinica)* was founded in September 1980, and the first Editor-in-chief was Prof Guang-sheng DING. *APS* was published quarterly at the beginning, bimonthly since 1986, and monthly since 1999. From the year of 2000, *APS* published all articles in English and extended its scope to all areas of pharmacology and the life sciences. From January 2009, *APS* was co-published with Nature Publishing Group, a division of Macmillan Publishers Ltd, in association with the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and the Chinese Pharmacological Society. Now the Editor-in-chief is Prof Jian DING.


*APS* is China's leading journal in pharmacology and pharmacy with an impact factor of 1.783 (2009 Journal Citation Reports, Thomson Reuters 2010). The journal is abstracted or indexed in: BIOSIS, CA, CSA Medical Biotechnology, CSA Bioengineering, CSA Neuroscience, Current Contents/Life Sciences, Excerpta Medica, FSTA, Global Health, IndexCopernicus, Index Medicus/MEDLINE, Kagaku Gijutsu Bunken Sokuho (Japan), VINITI (Russia), Research Alert, Science Citation Index, SciSearch, Scopus, Tropical Diseases Bulletin, *etc.*

*APS* now uses the ScholarOne Manuscripts system for online submission and peer review. Authors can submit their manuscripts at the website <http://mc.manuscriptcentral.com/aphs>. For further details about *APS* and how to submit, see the Instructions for Authors at [www.chinaphar.com](http://www.chinaphar.com), or contact the Editorial Office through [aps@mail.shcnc.ac.cn](mailto:aps@mail.shcnc.ac.cn).

*APS* is online at [www.nature.com/aps](http://www.nature.com/aps). Visit the journal's home pages for details of the aims and scope, readership, and instructions to authors. Use the website to order a subscription, reprints, a sample copy or individual articles. Full text of all articles published before 2009 are free to all readers. Articles published from January 2009 are free 12 months after publication.

*APS* is supported by grants from Natural Science Foundation of China (NSFC), the China Association for Science and Technology (CAST), and the Scientific Publishing Foundation of Chinese Academy of Sciences (SPFCAS).

[www.nature.com/aps](http://www.nature.com/aps) [www.chinaphar.com](http://www.chinaphar.com)





## 赞助单位

**BIO-RAD**

上海伯乐生命医学产品(上海)有限公司

通用电气医疗系统贸易发展(上海)有限公司



厦门建发股份有限公司

上海建发实业有限公司

上海建发有限公司

Eppendorf Biotechnology International Trade Co., Ltd

OLYMPUS(中国)有限公司上海分公司

东方科学仪器上海进出口有限公司

创腾科技有限公司

### 会务组联系方式

吴民淑: 13661965692

朱倩蓉: 13681876381

黄 娟: 13764230546

许 嘉: 13918107540

何胡军: 13816578368

张 华: 13641838661

Acta Pharmacologica Sinica

Add: 294 Tai-Yuan Road, Shanghai 200031, China

Phn: 86-21-5492-2821. Fax: 86-21-5492-2823

E-mail: [aps@mail.shcnc.ac.cn](mailto:aps@mail.shcnc.ac.cn) & [aps@sibs.ac.cn](mailto:aps@sibs.ac.cn)